e-Drug3D

2167

REMIBRUTINIB

INN
REMIBRUTINIB

cas 1787294-07-8

CLASS

ANTINEOPLASTIC
IMMUNOMODULATOR
BTK KINASE INHIBITOR
TREATMENT OF CHRONIC SPONTANEOUS URTICARIA (CSU)

ROUTE (list)

ORAL

ATC code

L04AA60

PK parameters

Tmax 1 HOUR
VD 1238 LITER
Cl 160 LITER / HOUR
PPB 95.4 PERCENT
t1/2 1.5 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET BRUTON TYROSINE KINASE (BTK)

PDB
6TFP (BTK IN COMPLEX WITH LOU064 A POTENT AND HIGHLY SELECTIVE COVALENT INHIBITOR)

Download experimental 3D coordinates of N6Z with added hydrogens

Download SDF file

Benzamide, N-[3-[6-amino-5-[2-[methyl(1-oxo-2-propen-1-yl)amino]ethoxy]-4-pyrimidinyl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluoro-

Formula:
C27H27F2N5O3

Calculated chemical properties:

MW 507.54
NB_atoms 37
XLogP 4.47
PSA 90.333
NB_HD 3
NB_HA 8
fsp3 0.26
Lipinski(0=no;1=yes) 0

FDA
NDA 218436 (label) INN (REMIBRUTINIB) RHAPSIDO (NOVARTIS) APPROVAL= AP YEAR= 2025 NEWMOLECULARENTITY